What is ACHC's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ACHC.

Stock Ratings / Health Care / ACHC / options

CLOV (36) CELC (31) FTRE (32) VCYT (73) ⌘ Pro Terminal →

Acadia Healthcare Company Inc. (ACHC) Options Positioning, Max Pain & Unusual Sweeps

$29.62 -1.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.50

Acadia Healthcare Company Inc. (ACHC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.79B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACHC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Acadia Healthcare Company Inc. (NASDAQ: ACHC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $29.62 (-1.13% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ACHC ranks #498 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACHC compare to CLOV and CELC in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), ACHC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -24.8%. By comparison, CLOV (Clover Health Investments Corp. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -29.3%, cap $2.37B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACHC?

▼

Per ACHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520697), Acadia Healthcare Company Inc. generated $3.31B in revenue (+5.0% YoY), -$1.10B in net income, and -$439.9M in free cash flow against $5.53B in total assets and $2.47B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $29.50 (-0.39%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACHC)Realized 20D OHLCV Swing Band: ±8%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY ACHC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (37% of score)

20D Institutional Volume Accumulation (±8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (21% of score)

FRED Regime × Technicals: 75% of 52W Range • RSI-14 at 50.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$31.67-0.8% Next Q

Q2 (-2Q)

Grade D$31.43-6.1% Next Q

Q3 (-1Q)

Grade D$29.51+0.4% Next Q

Current

Grade D-$29.62-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACHC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACHC currently carries a cautious 38/100 (D-) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($29.13) and Max Pain ($31.10) forces dealer call-delta covering toward $37.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACHC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ACHC)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ACHC.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHC)

✓Walkthrough of ACHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.97%📐 HORIZONTAL RANGE

2026-11-03O $29.46H $29.96L $29.46C $29.62VOL 2.58M

RES: $32.33SUP: $26.81SMA50: $29.13SMA200: $26.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACHC Butterfly Map → + Track ACHC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.6%/yr Implied 5Y Growth

vs. +5.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHC)

Health Care Rank #498 of 1016 ⚔️ CLOV vs ACHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACHC vs. CLOV, CELC, FTRE, VCYT)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Acadia Healthcare Company Inc. (ACHC) ranks #498 by composite RQD confidence (38/100, grade D-) and #213 by equity capitalization ($2.79B). Within this direct 5-issuer industry benchmark cohort, VCYT leads on earnings valuation at 63.2x trailing P/E, while VCYT leads on capital efficiency and profitability with 4.6% ROIC and 70.1% gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with ACHC at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACHC ACTIVE Acadia Healthcare Company Inc.	D-	38/100	—	—	-24.8%	-1.13%	$2.79B	Benchmark Subject
CLOV Clover Health Investments Corp. (Class A)	D-	36/100	—	—	-29.3%	-3.36%	$2.37B	/clov-vs-achc →
CELC Celcuity Inc.	E	31/100	—	—	-35.0%	-2.98%	$3.38B	/celc-vs-achc →
FTRE Fortrea Holdings Inc.	E	32/100	—	—	-35.0%	-5.96%	$2.05B	/ftre-vs-achc →
VCYT Veracyte Inc.	B	73/100	63.2x	70.1%	4.6%	-2.02%	$4.02B	/vcyt-vs-achc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001520697

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acadia Healthcare Company Inc. (ACHC) reported GAAP revenue of $3.31B (+5.0% vs. FY2024 revenue of $3.15B , and +13.1% cumulative change since FY2023) , GAAP net income of -$1.10B, operating cash flow of $131.9M, and free cash flow of -$439.9M (+21.5% YoY). On the balance sheet, ACHC closed FY2025 with $5.53B in total assets against $2.47B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.31B	-$1.10B	$131.9M	-$439.9M	$5.53B	$2.47B
FY2024 (FY)	2024-12-31	$3.15B	$255.6M	$129.7M	-$560.7M	$5.96B	$1.88B
FY2023 (FY)	2023-12-31	$2.93B	-$21.7M	$462.3M	$330.5M	$3.51B	$822.4M

3. ACHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACHC compare to CLOV and CELC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACHC?

Where is ACHC trading relative to its 50-day, 200-day, and 52-week technical levels?

ACHC last traded at $29.62 (-1.13% on volume of 1,256,354 shares), positioning the stock +1.68% above its 50-day simple moving average ($29.13) and +13.70% above its 200-day simple moving average ($26.05). Across its 52-week range of $11.43 to $35.83, ACHC sits at the 74.5% percentile with a 14-day RSI of 50.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($27.25 to $31.99).

Direct Sub-Reports: ACHC RQD Cockpit ACHC 12M Forecast ACHC Earnings & Move ACHC Dividends & DRIP ACHC Insiders & 13F ACHC Whale Options ACHC Profit Sankey ACHC News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ACHC — Acadia Healthcare Company Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:25:04Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ACHC scores 37 out of 100, a letter grade of D-, and the verdict label is "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (5 / 20): Per the RQD rating, ROIC is -24.8% and FCF yield is -16.04%.
Whale 13F Flow (13 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. Investor implication: institutional interest is a partial offset, but it is not strong enough to lift the composite score.
Insider Conviction (6 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data. Investor implication: insider signals are weak in the composite, reducing confidence in management's own view of near-term value.
Macro Regime Fit (8 / 20): Per the RQD rating, beta is 1.07 and the score reflects sector sensitivity. Investor implication: the stock tends to move roughly in line with the market, with no defensive cushion from its macro profile.
Forensic Balance Sheet (5 / 20): Per the RQD rating, Altman Z is 0.45, Piotroski F is 5/9, and Debt/Equity is 1.27. Investor implication: the low Altman Z is in the distress-risk range, and leverage is high relative to equity. This is the most significant constraint on the thesis.

Valuation tradeoff: The forward P/E of 21 is per the market data section. Against trailing EPS of -11.84, the stock is priced on expected recovery rather than current earnings. A prospective investor is therefore underwriting a turnaround, not paying for demonstrated profitability.

2. Business Model, Unit Margins & SEC Financial Trajectory

Acadia Healthcare Company Inc. Is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry. The profile does not describe its products, customers, or revenue model. The company reported revenue of $3.31B for FY 2025, indicating a substantial operating scale.

Revenue grew from $2.93B in FY 2023 to $3.31B in FY 2025, but FY 2025 operating income swung to -$1.30B and net income to -$1.10B. Market data shows an operating margin of -40.6% and a net margin of -33.3%, and ROIC of -24.8%. The Altman Z-Score of 0.45 and Piotroski F-Score of 5/9 are per the RQD rating. Debt rose from $822.4M in FY 2023 to $2.47B in FY 2025 against cash of $133.2M, a balance sheet posture the RQD rating classifies as vulnerable.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Forward P/E of 21 against negative trailing EPS suggests the market is pricing in a recovery, and two news headlines frame the stock as undervalued. With Fundamental Cash Engine at 5/20 (ROIC -24.8%, FCF yield -16.04%) and Institutional Whale Flow at 14/20, sustained execution supports upside toward the top of the $11.43 – $35.83 52-week range.
🐻 Primary Bear Case: Altman Z of 0.45, Debt/Equity of 1.27, FCF yield of -16.04%, and ROIC of -24.8% place the balance sheet and cash engine in the weakest tier of the RQD rating. Investors must weigh current valuation against -40.6% operating margins and a 1.07 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level input is beta of 1.07 and the Health Care / Medical Specialities classification.

Key Question #1: What drove the swing from FY 2024 net income of $255.6M to FY 2025 net loss of -$1.10B, and is it recurring or one-time?
Key Question #2: What is the composition of the $2.47B debt, its maturity schedule, and its interest cost?
Key Question #3: Do the "undervalued" headlines rest on a sales-based or growth-based model, and what assumptions do they use?

ACHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acadia Healthcare Company Inc. (ACHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACHC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Acadia Healthcare (ACHC) Stock May Be Below Fair Value On Sales

Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 23h ago

Acadia Healthcare Company (ACHC) Could Be 11% Undervalued On Its Growth Narrative

Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Acadia Healthcare Company, Inc. Estimates – NASDAQ:ACHC

TradingView report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Acadia Healthcare Company (ACHC) Rebounds Sharply, Is The Stock Still A Bargain?

Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Acadia Healthcare (ACHC): Buy, Sell, or Hold Post Q2 Earnings?

Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Acadia Healthcare Company Inc. (ACHC) Affects Rotational Strategy Timing

Stock Traders Daily report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

What Acadia Healthcare Stock Momentum Means For Shareholders

Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Raymond James sets USD 39.00 target for Acadia Healthcare stock

ad-hoc-news.de report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACHC Bull vs. Bear Conversation Board — What's Your Call at $29.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACHC 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $38.05 (+27.0%)

📌 Pinned Debate

Forward P/E of 21 against negative trailing EPS suggests the market is pricing in a recovery, and two news headlines frame the stock as

Forward P/E of 21 against negative trailing EPS suggests the market is pricing in a recovery, and two news headlines frame the stock as undervalued.. When you look under the hood at ACHC, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -24.8% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (14/20) has been quietly accumulating below $35.83. My 12M target is $38.05.

CapAlloc_Nerd 🐂 BULL

@RedlineAuditor Fair point on 21.0x forward P/E, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH 🎯 Target: $23.07 (-23.0%)

Spot @ $29.96

Altman Z of 0.45, Debt/Equity of 1.27, FCF yield of -16.04%, and ROIC of -24.8% place the balance sheet and cash engine in the weakest

Careful chasing ACHC at $29.96. Altman Z of 0.45, Debt/Equity of 1.27, FCF yield of -16.04%, and ROIC of -24.8% place the balance sheet and cash engine in the weakest tier of the RQD rating.. Gross margin is 0.0%, but operating margin is -40.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $23.07 on multiple compression.